Getting a new lab space? Design it for safety now and save thousands later

By Dan Scungio, MT (ASCP), SLS, CQA (ASQ)  bio Let me tell you a story. Once upon a time, there was a laboratory manager who worked in a hospital that was designing a new stand-alone … [Read more...]


Diagnostic Deals: A Roundup of the Key Mergers, Acquisitions, Alliances, Licenses and Other Strategic Transactions From the Past Month

The big story of April wasn't any particular new deal but the apparent resolution of an old one—the Abbott-Alere merger. Deal volume remained brisk, particularly in the alliance arena. But for those … [Read more...]


5 ways to end generational stereotyping in your lab

By Dr. William A. Schiemann  bio These days, the Millennial Generation is hyped, perhaps even more than Baby Boomers were hyped in the 1950s and 1960s. As I meet with executives around the … [Read more...]


FDA Watch: Congress Kills Trump Plan to ‘Recalibrate’ User Fees

Instead of the budget cuts the President asked for, the newly approved federal government spending plan increases FDA funding by $103 million, $4.665 billion in total. That includes $2.759 billion for … [Read more...]


CORRECTION: Molecular Assays Stave Off Big Cuts in 2017 Clinical Laboratory Fee Schedule

  Editor's Note: The lead story in the November 25, 2016 issue of LIR is about changes to the 2017 Clinical Laboratory Fee Schedule affecting reimbursement for clinical laboratory tests. The … [Read more...]


Diagnostics Earnings Show Gains in 1st Q

The laboratory industry is off to a strong start in 2017. Although growth rates varied, most firms were up for the quarter. Here's an overview of 1Q 2017 based on the earnings reports we've seen so … [Read more...]


The Dx Pipeline
A roundup of the month’s key new product launches

As usual, genome and sequencing products dominated the diagnostics pipeline last month. Exceptions included rapid diagnostic testing products from Alere, oncology lung testing kits from IncellDx, … [Read more...]


23andMe Wins FDA Approval for DTC Genetic Test

23andMe and the U.S. Food and Drug Administration (FDA) announced this month that the agency has allowed marketing of 23andMe's Personal Genome Service Genetic Health Risk (GHR) tests for 10 diseases … [Read more...]


ACA Impacts Screening Test Usage

As efforts to replace the Affordable Care Act (ACA) have not yet resulted in its repeal, it appears there has been an uptick in preventive screening caused by the ACA. Yet, cancer-screening rates in … [Read more...]


CMS Enforcement Discretion Eases Pressure on Labs

After we went to press last month, the Centers for Medicare and Medicaid Services (CMS) announced just in the nick of time that it wouldn't impose civil monetary penalties against labs which failed to … [Read more...]